Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” i.e. one of the most exciting biotech companies in the industry.
The award highlights significant company growth and advancement in the field of RNA modifying enzymes (RME) as STORM aims to become the global leader in the field of RME.
Under the new leadership of Jerry McMahon as Chief Executive Officer, STORM is accelerating progress in its pipeline and discovery platform. Its first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on track to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
STORM is focused on harnessing the power of RNA modification and developing novel treatments for the unmet medical needs of patients with cancer and other diseases.